Model A   Model B   Model C   Model D  
  β p-value β p-value β p-value β p-value
Age -0.016 0.86 0.002 0.98 0.007 0.95 -0.027 0.78
Sex
(men/women)
-0.164 0.10 -0.196 0.042 -0.280 0.010 -0.056 0.63
Diabetes (yes/no) 0.231 0.76 -0.070 0.50 0.026 0.83 -0.009 0.94
MetS (yes/no) 0.108 0.32 -0.057 0.61 0.131 0.26 0.147 0.19
VLDL particle concentration 0.243 0.013     0.213 0.049 0.304 0.004
LDL particle concentration 0.402 0.006 0.249 0.011     0.360 0.002
HDL particle concentration -0.057 0.96 -0.018 0.85 -0.063 0.56    
Large VLDL     0.493 <0.001        
Medium VLDL     -0.059 0.63        
Small VLDL     -0.045 0.63        
IDL         0.161 0.091    
Large LDL         -0.033 0.75    
Small LDL         0.084 0.49    
Large HDL             0.130 0.33
Medium HDL             0.049 0.67
Small HDL             -0.115 0.34
VLDL: very low density lipoproteins; LDL: low density lipoproteins; HDL: high density lipoproteins. β: standardized regression coefficient.
Model A: model including age, sex, diabetes status, presence of MetS, VLDL, LDL and HDL particle concentrations
Model B: model including age, sex, diabetes status, presence of MetS, VLDL subfractions, and LDL and HDL particle concentrations
Model C: model including age, sex, diabetes status, presence of MetS, LDL subfractions, and VLDL and HDL particle concentrations
Model D: model including age, sex, diabetes status, presence of MetS, HDL subfractions, and VLDL and LDL particle concentrations
Table 5: Multivariable linear regression analysis demonstrating relationships of plasma apolipoprotein E with lipoprotein subfraction characteristics in APOE ε3/ε3 and ε3/ε4 carriers (52 subjects with metabolic syndrome (MetS) and 60 subjects without MetS).